=> d ibib ab 1-9

L3 ANSWER 1 OF 9 USPATFULL
ACCESSION NUMBER: 1999:24300 USPATFULL
TITLE: Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
INVENTOR(S): Smith, James A., Chatham, MA, United States
PATENT ASSIGNEE(S): Creative Products Resource Associates Inc., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5874074	19990223
APPLICATION INFO.:	US 1997-804084	19970221 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-480534, filed on 7 Jun 1995, now patented, Pat. No. US 5658559 which is a continuation of Ser. No. US 1994-220394, filed on 30 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-992887, filed on 16 Dec 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Harrison, Robert H.
LEGAL REPRESENTATIVE: Pillsbury Madison & Sutro Intellectual Property Group
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 711
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is an occlusive or semi-occlusive barrier moisturizing lotion useful for treating pathologies of the skin. The lotion is composed of an oil-in-water emulsion that includes water, one or more emollients, at least one polyhydric alcohol, a barrier polymer, and a therapeutical agent, preferably a dermatological agent such as a steroid. When the lotion is applied to the skin and dries, a polymeric film forms on the surface of the lotion to retain the therapeutic agent in contact with the surface of the skin. The emollient system of the lotion provides a moisturizing and soothing effect on the skin, and the occlusive/semi-occlusive nature of the lotion causes hydration of the skin to facilitate and enhance penetration of the drug into the skin.

L3 ANSWER 2 OF 9 USPATFULL
ACCESSION NUMBER: 97:73278 USPATFULL
TITLE: Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder
INVENTOR(S): Smith, James A., Chatham, MA, United States
PATENT ASSIGNEE(S): Creative Products Resource Associates, Ltd., North Caldwell, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5658559	19970819
APPLICATION INFO.:	US 1995-480534	19950607 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1994-220394, filed on 30 Mar 1994, now abandoned which is a continuation of Ser. No. US 1992-992887, filed on 16 Dec 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hulina, Amy
LEGAL REPRESENTATIVE: Cushman Darby & Cushman IP Group of Pillsbury Madison & Sutro, LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
LINE COUNT: 638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is an occlusive or semi-occlusive barrier moisturizing lotion useful for treating pathologies of the skin. The lotion is composed of an oil-in-water emulsion that includes water, one or more emollients, at least one polyhydric alcohol, a barrier polymer, and a therapeutical agent, preferably a dermatological agent such as a steroid. When the lotion is applied to the skin and dries, a polymeric film forms on the surface of the lotion to retain the therapeutic agent in contact with the surface of the skin. The emollient system of the lotion provides a moisturizing and soothing effect on the skin, and the occlusive/semi-occlusive nature of the lotion causes hydration of the skin to facilitate and enhance penetration of the drug into the skin.

L3 ANSWER 3 OF 9 USPATFULL
ACCESSION NUMBER: 95:50185 USPATFULL
TITLE: Stable cream and lotion bases for lipophilic drug compositions
INVENTOR(S): Munayyer, Farah J., West Caldwell, NJ, United States
Sequeira, Joel A., New York, NY, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5422361	19950606
	WO 9108733	19910627
APPLICATION INFO.:	US 1992-859494	19920612 (7)
	WO 1990-US7228	19901214
		19920612 PCT 371 date
		19920612 PCT 102(e) date

RELATED APPLN. INFO.: Continuation of Ser. No. US 1989-453564, filed on 20 Dec 1989, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Criares, T. J.
LEGAL REPRESENTATIVE: Hoffman, Thomas D.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 913
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A cosmetically elegant, physically and chemically stable base in the form of an oil-in-water emulsion for use in cream and lotion lipophilic drug containing- pharmaceutical compositions containing at least one lipophilic drug and an effective amount of N-methyl-2-pyrrolidone is disclosed.

L3 ANSWER 4 OF 9 USPATFULL
ACCESSION NUMBER: 95:33913 USPATFULL
TITLE: Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents
INVENTOR(S): Eisen, Drore, 6720 Beechlands Dr., Cincinnati, OH, United States 45237

	NUMBER	DATE
PATENT INFORMATION:	US 5407663	19950418
APPLICATION INFO.:	US 1994-222277	19940404 (8)

DISCLAIMER DATE: 20110510
RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-6287, filed on 15 Jan 1993, now patented, Pat. No. US 5310545 which is a continuation-in-part of Ser. No. US 1992-963485, filed on 21 Oct 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-802646, filed on 9 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-683380, filed on 11 Apr 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Mars, Howard T.
ASSISTANT EXAMINER: Cook, Rebecca
LEGAL REPRESENTATIVE: Hendricks, Glenna; Gates, Stephen
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
LINE COUNT: 422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Patients may effectively be treated for inflammatory conditions of the mouth using aqueous anti-inflammatory steroids in solutions that can be swished and expectorated as a mouthwash. Such therapy would allow direct contact of the medication with the diseased mucous membranes and would contact areas of the oral cavity that would not usually be reached with application of creams, gels, or ointments. Compositions containing antifungal agents in addition to steroids are particularly useful.

Swishing for three to five minutes, then expectorating the aqueous anti-inflammatory-containing, results in maintenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels containing those agents. The mode of application is simple and is not repugnant to the patient as is the application of creams, gels, or ointments.

L3 ANSWER 4 OF 9 USPATFULL (Continued)

L3 ANSWER 5 OF 9 USPATFULL
ACCESSION NUMBER: 94:39864 USPATFULL
TITLE: Method of treatment using mouthwashes containing steroids and antifungal agents and compositions of matter
INVENTOR(S): Eisen, Drore, 6720 E. Beechlands Dr., Cincinnati, OH, United States 65237

	NUMBER	DATE
PATENT INFORMATION:	US 5310545	19940510
APPLICATION INFO.:	US 1993-6287	19930115 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1992-963485, filed on 21 Oct 1992 And a continuation-in-part of Ser. No. US 1991-802646, filed on 9 Dec 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-683380, filed on 11 Apr 1991, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Cintins, Marianne M.
ASSISTANT EXAMINER: Cook, Rebecca
LEGAL REPRESENTATIVE: Hendericks, Glenna; Gates, Stephen
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 408
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions used to treat inflammatory diseases of the mouth contain anti-inflammatory steroids in combination with antifungal drugs in an aqueous medium as a mouthwash. Swishing for three to five minutes, then expectorating the mouthwashes results in maintenance of contact of the active agents with the oral cavity surfaces for a longer time than would application of gels containing those agents. The mode of application is simple and is not repugnant to the patient as is the application of creams, gels, or ointments.

L3 ANSWER 6 OF 9 USPATFULL
ACCESSION NUMBER: 91:89045 USPATFULL
TITLE: Glyceryl acetate ointment vehicles
INVENTOR(S): Dow, Gordon J., 506 Sequoia Ave., San Anselmo, CA, United States 94960
Dow, Debra A., San Rafael, CA, United States
PATENT ASSIGNEE(S): Dow, Gordon Jay, Mill Valley, CA, United States (U.S. individual)

	NUMBER	DATE
PATENT INFORMATION:	US 5061700	19911029
APPLICATION INFO.:	US 1989-438372	19891116 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Townsend and Townsend
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 642
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions of matter serving as topical ointment vehicles and comprising a glyceryl acetate, preferably triacetin, and an oleaginous material that can be combined with a medicament, preferably a corticosteriod, are described. The glyceryl acetate component functions as a solvent for the medicament. Additionally, methods of use for treating skin disorders comprising the topical application of a therapeutically effective amount of a medicament in a composition of the invention are detailed.

L3 ANSWER 7 OF 9 USPATFULL
ACCESSION NUMBER: 88:63905 USPATFULL
TITLE: Steroid lotion
INVENTOR(S): Sequeira, Joel A., New York, NY, United States
Munayyer, Farah J., West Caldwell, NJ, United States
Galeos, Rebecca, Bloomfield, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4775529	19881004
APPLICATION INFO.:	US 1987-53172	19870521 (7)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Rose, Shep K.
LEGAL REPRESENTATIVE: Maitner, John J.; Miller, Stephen I.; Nelson, James R.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 291
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB An improved lotion formulation for the topical administration of corticosteroids in a hydro-alcoholic base containing propylene glycol.

L3 ANSWER 8 OF 9 USPATFULL
ACCESSION NUMBER: 78:62796 USPATFULL
TITLE: 7.alpha.-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
INVENTOR(S): Green, Michael J., Kendall Park, NJ, United States
Shue, Ho-Jane, Belleville, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4124707	19781107
APPLICATION INFO.:	US 1977-848856	19771107 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1976-753256, filed on 12 Dec 1976, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: King, Mary S.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1,23
LINE COUNT: 3271
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel 3,20-dioxo-7.alpha.-halogeno-1,4-pregnadienes are described and their use as anti-inflammatory agents. Preferred are 7.alpha.-bromo- and 7.alpha.-chloro- derivatives, particularly 7.alpha.-bromo- and 7.alpha.-chloro-1,4-pregnadienes-11.beta.,17.alpha.,21-triol-3,20-dione 17,21-dihydrocarboncarboxylates, the 16-methyl and 16-methylene derivatives thereof being particularly valuable as topical anti-inflammatory agents.

L3 ANSWER 9 OF 9 USPATFULL (Continued)

L3 ANSWER 9 OF 9 USPATFULL
ACCESSION NUMBER: 78:11581 USPATFULL
TITLE: Process for the preparation of 7.alpha.-halogeno-3-oxo-4-dehydro steroids and novel 7.alpha.-halogeno derivatives produced thereby
INVENTOR(S): Green, Michael J., Kendall Park, NJ, United States
Shue, Ho-Jane, Belleville, NJ, United States
Shapiro, Elliot L., Cedar Grove, NJ, United States
Gentles, Margaret A., Bloomfield, NJ, United States
PATENT ASSIGNEE(S): Schering Corporation, Kenilworth, NJ, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 4076708	19780228
APPLICATION INFO.:	US 1976-753257	19761222 (5)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Roberts, Elbert L.
LEGAL REPRESENTATIVE: King, Mary S.; Coan, Stephen B.
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
LINE COUNT: 1422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB 3-Oxo-6-unsubstituted-7.alpha.-halogeno-4-dehydro steroids, wherein said halogen is chlorine, bromine or iodine, are prepared by reaction of a 3-oxo-6,7-di-unsubstituted-4,6-bis-dehydro steroid with at least an equimolar quantity of the corresponding hydrogen halide in a non-reactive organic solvent at temperatures no higher than about 30.degree. C, and then are isolated by removal of said solvent and any excess acid at temperatures no higher than about 25.degree. C without subjecting said 3-oxo-6-unsubstituted-7.alpha.-halogeno-4-dehydro steroid to a basic medium.

A preferred species of this process is that wherein the starting steroid is a 3,20-dioxo-9-unsubstituted-11-oxygenated-1,4,6-pregnatriene-17,21-diol or ester thereof, preferably a 17,21-di-lower alkanoate or a 17-benzoate 21-lower alkanoate ester thereof, whereby is prepared in good yields a 3,20-dioxo-7.alpha.-halogeno-1,4-pregnadiene-17.alpha.,21-diol or ester thereof, useful as topical anti-inflammatory agents.

Also described are novel 3,20-dioxo-7.alpha.-halogeno-4-pregnene-17.alpha.,21-diols and esters thereof having anti-inflammatory activity as well as 3-oxo-7.alpha.-halogeno-17.alpha.-4-pregnene-21,17.beta.-carbolactone aldosterone antagonists.

=> d ibib ab hit 1-7

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:522135 CAPLUS
DOCUMENT NUMBER: 131:134676
TITLE: Antipsoriatic nail polishes containing glucocorticoids
INVENTOR(S): Bohn, Manfred; Kraemer, Karl Theodor
PATENT ASSIGNEE(S): Hoechst Marion Roussel Deutschland GmbH, Germany
SOURCE: Can. Pat. Appl., 13 pp.
CODEN: CPXXEB
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2245637	AA	19990221	CA 1998-2245637	19980820
EP 913154	A1	19990506	EP 1998-115049	19980811
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
NO 9803818	A	19990222	NO 1998-3818	19980820
ZA 9807531	A	19990222	ZA 1998-7531	19980820
CN 1209318	A	19990303	CN 1998-118470	19980820
AU 9880856	A1	19990304	AU 1998-80856	19980820
JP 11130679	A2	19990518	JP 1998-233671	19980820
PRIORITY APPLN. INFO.:			DE 1997-19736112	19970821

AB A nail polish comprises at least one glucocorticoid, at least one physiol. acceptable solvent and at least one water-insol. film-forming agent. The nail polish is suitable for the treatment of nail **psoriasis**. A nail polish contained clobetasol-17-propionate 8, Me vinyl ether-monobutyl maleate copolymer (in isopropanol) 30, isopropanol 31, and EtOAc 31 %.
AB A nail polish comprises at least one glucocorticoid, at least one physiol. acceptable solvent and at least one water-insol. film-forming agent. The nail polish is suitable for the treatment of nail **psoriasis**. A nail polish contained clobetasol-17-propionate 8, Me vinyl ether-monobutyl maleate copolymer (in isopropanol) 30, isopropanol 31, and EtOAc 31 %.
ST nail polish glucocorticoid polymer film **psoriasis**; clobetasol polyvinyl nail polish **psoriasis**
IT Nail (anatomical)
(disease, **psoriasis**; antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
IT **Psoriasis**
(in nail; antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)
IT 50-02-2, Dexamethasone 50-24-8, Prednisolone 53-03-2, Prednisone 67-73-2 72-80-0, Chlorquinaldol 76-25-5, Triamcinolone acetonide

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
76-47-1, Hydrocortamate 130-26-7, Clioquinol 152-97-6, Fluocortolone
356-12-7, Fluocinonide 382-67-2, Desoximetasone 426-13-1, Fluorometholone 638-94-8, Desonide 1255-35-2, Fluprednidene acetate
1524-88-5, Fludroxycortide 2002-29-1, Flumethasone pivalate 2152-44-5,
Betamethasone valerate 2193-87-5, Fluprednidene 3093-35-4, Halcinonide
3693-39-8, Fluclorolone acetonide 5534-09-8, Beclomethasone dipropionate
5593-20-4, Betamethasone dipropionate 7008-26-6, Dichlorisone 9004-57-3, Ethyl cellulose 9004-70-0, Cellulose nitrate 13609-67-1,
Hydrocortisone butyrate 19888-56-3, Fluazacort 22298-29-9, Betamethasone benzoate 23674-86-4, Difluprednate 25119-68-0, Methyl
vinyl ether-monobutyl maleate copolymer 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 25212-88-8, Methacrylic
acid-ethyl acrylate copolymer 33564-31-7, Diflorasone diacetate 50629-82-8, Halometasone 51022-69-6, Amcinonide 51333-22-3, Budesonide
53716-43-1, Bendacort 55461-42-2, Flupamesone 59198-70-8, Diflucortolone valerate 61951-99-3, Tixocortol **66734-13-2**, Alclometasone dipropionate 67907-01-1 73771-04-7, Prednicarbate 83919-23-7, Mometasone furoate 86401-95-8, Methylprednisolone aceponate
RL: BUU (Biological use, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(antipsoriatic nail polishes contg. glucocorticoids and film-forming polymers)

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1998:603197 CAPLUS
DOCUMENT NUMBER: 129:184277
TITLE: Tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**
INVENTOR(S): Sefton, John
PATENT ASSIGNEE(S): Vision Pharmaceuticals L.P., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9836753	A1	19980827	WO 1998-US3355	19980220
W: AU, CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9866618	A1	19980909	AU 1998-66618	19980220
EP 969847	A1	20000112	EP 1998-908631	19980220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1997-39151	19970220
			WO 1998-US3355	19980220

AB A method for treating proliferative **skin** diseases comprises the administration of an effective amt. of tazarotene and an effective amt. of a corticosteroid. This invention is esp. useful for treating **psoriasis**.
TI Tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**
AB A method for treating proliferative **skin** diseases comprises the administration of an effective amt. of tazarotene and an effective amt. of a corticosteroid. This invention is esp. useful for treating **psoriasis**.
ST **skin** proliferative disorder tazarotene corticosteroid; **psoriasis** tazarotene corticosteroid
IT **Skin** tumors
(inhibitors; tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)
IT **Skin** diseases
(proliferative; tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)
IT Antitumor agents
(**skin**; tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)
IT Antiproliferative agents
Creams (drug delivery systems)
Drug interactions
Gels (drug delivery systems)
Psoriasis
Topical drug delivery systems

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
(tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)
IT Corticosteroids, biological studies
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)
IT 50-03-3, Hydrocortisone acetate 67-73-2, Fluocinolone acetonide 356-12-7, Fluocinonide 807-38-5, Fluocinolone 2152-44-5, Betamethasone
valerate 5593-20-4, Betamethasone dipropionate 25122-46-7, Clobetasol
propionate 33564-31-7, Diflorasone diacetate **66734-13-2**, Alclometasone dipropionate 80474-14-2, Fluticasone propionate 83919-23-7, Mometasone furoate 118292-40-3, Tazarotene
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(tazarotene and corticosteroid treatment for **skin** proliferation disorders, including **psoriasis**)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1998:323140 CAPLUS
DOCUMENT NUMBER: 129:19685
TITLE: Synergistic gold and corticosteroid-containing compositions
INVENTOR(S): Thomas, Richard Edward
PATENT ASSIGNEE(S): Medical Innovations Ltd., Australia; Thomas, Richard Edward
SOURCE: PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9819683	A1	19980514	WO 1997-AU747	19971104
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9747671	A1	19980529	AU 1997-47671	19971104
EP 954321	A1	19991110	EP 1997-910157	19971104
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, PT, IE				
CN 1235550	A	19991117	CN 1997-199438	19971104
			AU 1996-3473	19961104
PRIORITY APPLN. INFO.:			WO 1997-AU747	19971104

AB This invention relates to a method of treating an immune-mediated disorder having one or more manifestations. The method comprises administering to a patient requiring such treatment a gold compd. and at least one corticosteroid, wherein the at least one corticosteroid is selected to interact synergistically with the gold compd. to exhibit preferential action towards one of the manifestations of said disorder or to exhibit equal action towards each manifestation of said disorder. The invention also relates to a pharmaceutical compn. suitable for use in the method. The synergistic effect of auranofin with various corticosteroids was

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
demonstrated with betamethasone dipropionate, fluocinolone acetonide and mometasone furoate being particularly effective in reducing epidermal hyperplasia and inflammation.
IT Anti-inflammatory drugs
Antiarthritics
Dermatitis
Immunological diseases
Injections (drug delivery systems)
Oral drug delivery systems
Psoriasis
Synergism
Topical drug delivery systems
(synergistic gold and corticosteroid-contg. compns.)
IT 50-02-2, Dexamethasone 50-03-3, Hydrocortisone acetate 50-23-7, Hydrocortisone 67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide 378-44-9, Betamethasone 2152-44-5, Betamethasone valerate 3093-35-4, Halcinonide 5593-20-4, Betamethasone dipropionate 7440-57-5D, Gold, compds. 29205-06-9 34031-32-8, Auranofin **66734-13-2**, Alclometasone dipropionate 83919-23-7, Mometasone furoate
RL: BAC (Biological activity or effector, except adverse); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(synergistic gold and corticosteroid-contg. compns.)

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1997:533539 CAPLUS
DOCUMENT NUMBER: 127:210356
TITLE: Glucocorticoids and zinc compound for the treatment of **skin** disorders.
INVENTOR(S): Story, Michael John; Williams, Desmond Berry
PATENT ASSIGNEE(S): Bellara Medical Products Ltd., Australia; Story, Michael John; Williams, Desmond Berry
SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9727862	A1	19970807	WO 1997-AU48	19970130
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9715365	A1	19970822	AU 1997-15365	19970130
			AU 1996-7847	19960202
PRIORITY APPLN. INFO.:			WO 1997-AU48	19970130

AB A method for the treatment of **skin** disorders comprises the application of a formulation consisting of a glucocorticosteroid and a pharmaceutically acceptable zinc compd. The zinc compd. may be zinc monoglycerolate. The efficacy of topical zinc monoglycerolate was equiv. to that of 1% hydrocortisone ointment in the treatment of atopic dermatitis.
TI Glucocorticoids and zinc compound for the treatment of **skin** disorders.
AB A method for the treatment of **skin** disorders comprises the application of a formulation consisting of a glucocorticosteroid and a pharmaceutically acceptable zinc compd. The zinc compd. may be zinc monoglycerolate. The efficacy of topical zinc monoglycerolate was equiv. to that of 1% hydrocortisone ointment in the treatment of atopic dermatitis.
ST **skin** disorder glucocorticoid zinc compd; topical glucocorticoid zinc compd **skin** disorder
IT Atopic dermatitis
Creams (drug delivery systems)
Gels (drug delivery systems)

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2000 ACS (Continued)
Lotions (drug delivery systems)
Ointments (drug delivery systems)
Skin diseases
Topical drug delivery systems
(glucocorticoids and zinc compd. for treatment of **skin** disorders)
IT Glucocorticoids
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glucocorticoids and zinc compd. for treatment of **skin** disorders)
IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 53-36-1, Methylprednisolone acetate 67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide 303-40-2, Fluocortolone hexanoate 356-12-7, Fluocinonide 382-67-2, Desoximethasone 638-94-8, Desonide 1177-87-3, Dexamethasone acetate 1255-35-2, Fluprednidene acetate 1524-88-5, Fludroxycortide 2002-29-1, Flumethasone pivalate 2152-44-5, Betamethasone valerate 3093-35-4, Halcinonide 3693-39-8, Fluclorolone acetonide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 13609-67-1, Hydrocortisone butyrate 16754-68-0, Zinc monoglycerolate 22298-29-9, Betamethasone benzoate 23674-86-4, Difluprednate 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 29205-06-9, Fluocortolone pivalate 33564-31-7, Diflorasone diacetate 33755-46-3, Dexamethasone valerate 41767-29-7, Fluocortin butyl ester 51022-69-6, Amcinonide 55541-30-5, Dexamethasone dipropionate 59198-70-8, Diflucortolone valerate **66734-13-2**, Alclometasone dipropionate 72064-79-0 72590-77-3 73771-04-7, Prednicarbate 83919-23-7, Mometasone furoate 98651-66-2, Halobetasol
RL: BAC (Biological activity or effector, except adverse); THU (**Therapeutic use**); BIOL (Biological study); USES (Uses)
(glucocorticoids and zinc compd. for treatment of **skin** disorders)

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1996:656487 CAPLUS
DOCUMENT NUMBER: 125:284968
TITLE: Corticosteroid-containing pharmaceutical composition
INVENTOR(S): Jones, Julie Irene; Baker, Anthony Richard; Halls, Neil Graham; Watmough, Peter; Marriott, Peter
PATENT ASSIGNEE(S): Medeva Plc, UK
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9627376	A1	19960912	WO 1996-GB490	19960301
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
CA 2214436	AA	19960912	CA 1996-2214436	19960301
AU 9648851	A1	19960923	AU 1996-48851	19960301
AU 709320	B2	19990826		
EP 813413	A1	19971229	EP 1996-904935	19960301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1179720	A	19980422	CN 1996-192817	19960301
JP 11501045	T2	19990126	JP 1996-526697	19960301
CZ 285913	B6	19991117	CZ 1997-2758	19960301
BR 9607687	A	19991130	BR 1996-7687	19960301
			GB 1995-4265	19950303
PRIORITY APPLN. INFO.:			WO 1996-GB490	19960301

AB The present invention provides a foamable pharmaceutical compn. comprising a corticosteroid active substance, a quick-break foaming agent, a propellant, and a buffering agent. The quick-break foaming agent typically comprises an aliph. alc., water, a fatty alc. and surface active agent. The compns. of the invention can be used to treat various **skin** disease, and in particular scalp **psoriasis**. A claimed compn. contains betamethasone valerate 0.12, cetyl alc. 1.1, octadecan-1-ol 0.5, Polysorbate-60 0.4, ethanol 57.79, purified water 33.69, propylene glycol 2, anhyd. citric acid 0.073, K citrate 0.027, and butane/propane 4.3 %.

ST foam corticosteroid **skin** disease

IT Eczema
Psoriasis
(treatment of; corticosteroid-contg. pharmaceutical foamable compn.)

IT Scalp
(disease, **psoriasis**, treatment of; corticosteroid-contg. pharmaceutical foamable compn.)

IT **Skin**, disease
(intertrigo, treatment of; corticosteroid-contg. pharmaceutical foamable compn.)

IT 50-03-3, Hydrocortisone acetate 50-23-7, Hydrocortisone 53-36-1, Methylprednisolone acetate 67-73-2, Fluocinolone acetonide 76-25-5, Triamcinolone acetonide 152-97-6, Fluocortolone 356-12-7, Fluocinonide 382-67-2, Desoxymethasone 638-94-8, Desonide 1255-35-2, Fluprednidene acetate 1524-88-5, Flurandrenolone 2002-29-1, Flumethasone pivalate 2152-44-5, Betamethasone valerate 3093-35-4, Halcinonide 3693-39-8, Fluclorolone acetonide 5534-09-8, Beclomethasone dipropionate 5593-20-4, Betamethasone dipropionate 13609-67-1, Hydrocortisone butyrate 22298-29-9, Betamethasone benzoate 25122-46-7, Clobetasol propionate 25122-57-0, Clobetasone butyrate 33564-31-7, Diflorasone diacetate 41767-29-7, Fluocortin butyl 51022-69-6, Amcinonide 51333-22-3, Budesonide 59198-70-8, Diflucortolone valerate **66734-13-2**, Alclometasone dipropionate 83919-23-7, Mometasone furoate
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(corticosteroid-contg. pharmaceutical foamable compn.)

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1996:262517 CAPLUS
DOCUMENT NUMBER: 124:298941
TITLE: Water-base adhesive preparations of corticosteroids for **skin** diseases
INVENTOR(S): Ikeura, Yasuhiro; Tsuru, Seiichiro; Kubota, Jusuke
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08053354	A2	19960227	JP 1994-211951	19940811

AB The prepns. contain water-sol. polymers, moisturizers, H2O, dissolving agents and/or absorbefacients, and corticosteroids selected from diflucortolone valerate, difluprednate, prednisolone valerate acetate, hydrocortisone butyrate propionate, diflorasone acetate, dexamethasone propionate, betamethasone dipropionate, amcinonide, dexamethasone valerate, halcinonide, budesonide, and alclometasone propionate. The prepns. show moisturizing effect and are mild to **skin**, and are useful for treatment of eczema, dermatitis, **psoriasis**, erythema, sting by insects, chronic discotic erythematosus, lichen, atopic dermatitis, etc. A nonwoven fabric was coated with an adhesive compn. contg. H2O, gelatin, poly(vinyl alc.), kaolin, glycerin, poly(Na acrylate), methoxyethylene-maleic anhydride copolymer, diflucortolone valerate, and crotamiton to give a adhesive prepn. The prepn. showed **skin**-paling action upon application to forearm of healthy male volunteers and had slight **skin**-irritating effect.

TI Water-base adhesive preparations of corticosteroids for **skin** diseases

AB The prepns. contain water-sol. polymers, moisturizers, H2O, dissolving agents and/or absorbefacients, and corticosteroids selected from diflucortolone valerate, difluprednate, prednisolone valerate acetate, hydrocortisone butyrate propionate, diflorasone acetate, dexamethasone propionate, betamethasone dipropionate, amcinonide, dexamethasone valerate, halcinonide, budesonide, and alclometasone propionate. The prepns. show moisturizing effect and are mild to **skin**, and are useful for treatment of eczema, dermatitis, **psoriasis**, erythema, sting by insects, chronic discotic erythematosus, lichen, atopic dermatitis, etc. A nonwoven fabric was coated with an adhesive compn. contg. H2O, gelatin, poly(vinyl alc.), kaolin, glycerin, poly(Na acrylate), methoxyethylene-maleic anhydride copolymer, diflucortolone valerate, and crotamiton to give a adhesive prepn. The prepn. showed **skin**-paling action upon application to forearm of healthy male volunteers and had slight **skin**-irritating effect.

IT **Skin**, disease
(aq. corticosteroid adhesive prepns. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefacients for **skin** diseases)

IT Corticosteroids, biological studies
Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aq. corticosteroid adhesive prepns. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefacients for **skin** diseases)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint, aq. corticosteroid adhesive prepns. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefacients for **skin** diseases)

IT Pharmaceutical dosage forms
(topical, adhesive; aq. corticosteroid adhesive prepns. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefacients for **skin** diseases)

IT 56-81-5, Glycerin, biological studies 57-55-6, Propylene glycol, biological studies 100-51-6, Benzyl alcohol, biological studies 110-27-0, Isopropyl myristate 483-63-6, Crotamiton 3093-35-4, Halcinonide 5593-20-4, Betamethasone dipropionate 9002-89-5, Poly(vinyl alcohol) 9003-01-4, Poly(acrylic acid) 9003-04-7, Polyacrylic acid sodium salt 9003-39-8, Poly(vinylpyrrolidone) 9004-32-4, Carboxymethyl cellulose 9011-16-9, Methoxyethylene-maleic anhydride copolymer 23674-86-4, Difluprednate 25322-68-3, Polyethylene glycol 33564-31-7 33755-46-3, Dexamethasone valerate 51022-69-6, Amcinonide 51333-22-3, Budesonide 55541-30-5 59198-70-8, Diflucortolone valerate **66734-13-2** 72064-79-0 72590-77-3
RL: **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(aq. corticosteroid adhesive prepns. contg. water-sol. polymers, moisturizers, and dissolving agents and/or absorbefacients for **skin** diseases)

```
=> d his

     (FILE 'HOME' ENTERED AT 14:01:33 ON 20 JUL 2000)

     FILE 'REGISTRY' ENTERED AT 14:01:35 ON 20 JUL 2000
L1             1 S ALCLOMETASONE DIPROPIONATE/CN

     FILE 'USPATFULL' ENTERED AT 14:02:03 ON 20 JUL 2000
L2            11 S L1
L3             9 S L2 AND (PSORIAS? OR SKIN)

     FILE 'CAPLUS' ENTERED AT 14:04:48 ON 20 JUL 2000
L4            12 S L1/THU
L5             7 S L4 AND (PSORIAS? OR SKIN)
```

US 0936771208P1

Creation date: 01-08-2004
Indexing Officer: NNGUYEN6 - NGUYEN NGUYEN
Team: OIPEBackFileIndexing
Dossier: 09367712

Legal Date: 07-21-2000

No.	Doccode	Number of pages
1	CTFR	7
2	892	1

Total number of pages: 8

Remarks:

Order of re-scan issued on .....